#news
-
Press Releases
-
News
Thalassemia Foundation of Canada to Host its National Thalassemia Conference on October 23-24
The Thalassemia Foundation of Canada, a long-time member of TIF, will be holding its 2-day Virtual National Conference on Thalassaemia this weekend, October 23-24, at 12:00-16:00 EDT. The Conference aims at…
Weiterlesen » -
News
TIF Participates in EMA’s Annual Training Day 2020
TIF has participated in the Annual Training Day of the European Medicines Agency (EMA), held on 23 October 2020. TIF participants, Ms Lily Cannon (TIF Operations Manager) and Ms Eleni…
Weiterlesen » -
News
TIF Webinar Fridays Are Back With A New Session on „Heart Disease In Thalassaemia“
This Friday, 23 October 2020, at 15:00 EEST/13:00 BST, get ready to join Prof. Malcolm Walker and Dr. Dimitris Farmakis in our webinar on “Heart Disease In Thalassaemia“ for Patients/Parents,…
Weiterlesen » -
News
Johnson & Johnson Pauses Clinical Trials For Its Covid-19 Vaccine Over Participant’s Illness
Johnson & Johnson has paused its Covid-19 vaccine trial due to an “unexplained illness” in a participant, the company confirmed yesterday evening. The pharmaceutical giant was unclear if the patient…
Weiterlesen » -
News
Hidden Victims Of The Pandemic: Blood Bank Stocks Run Low As India’s Healthcare System Buckles
As public healthcare resources are redirected to halt the spread of coronavirus, victims of other life-threatening diseases pay the ultimate price. This recent news story, published by The Telegraph, depicts…
Weiterlesen » -
News
-
News
Fulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell Disease
Fulcrum Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that FTX-6058, its investigational treatment for sickle cell disease (SCD) and…
Weiterlesen » -
News
Pancyprian Thalassaemia Conference 2020
Τhe Pancyprian Thalassaemia Conference 2020 was successfully held on Saturday, 26 September, to discuss the modern scientific and other developments concerning thalassemia in Cyprus and worldwide. As a result of…
Weiterlesen » -
News
Health Canada Approves REBLOZYL® For Adult Patients with β-Thalassaemia
Bristol Myers Squibb Canada (BMS) and Acceleron Pharma Inc. announced today that Health Canada has approved REBLOZYL® (luspatercept) for the treatment of adult patients with red blood cell (RBC) transfusion-dependent anemia…
Weiterlesen »